Impax (IPXL) (TRGT) (WPI) (JBL) Ratings Reiterated

Impax Laboratories, Inc. (NASDAQ: IPXL), Targacept Inc. (NASDAQ: TRGT), Watson Pharmaceuticals Incorporated (NYSE: WPI) and Jabil Circuit, Inc. (NYSE: JBL) had ratings on them reiterated by analysts.

Ladenburg Thalmann reiterated its "Neutral" rating on Targacept Inc. (TRGT).

Jefferies (NYSE:JEF) reiterated its "Hold" rating on Watson Pharmaceuticals Incorporated (WPI). They have a price target of $70.00 on the company.

Collins Stewart reiterated its "Buy" rating on Impax Laboratories, Inc. (IPXL).

JPMorgan Chase & Co. (NYSE:JPM) reiterated its "Overweight" rating on Jabil Circuit, Inc. (JBL).

Biggest Losers (HP) (CCL) (IRBT) (HMC) (IPXL) on May 6

Among the big, negative movers on Friday, May 6, were Helmerich & Payne (HP), Carnival Corp. (CCL), IRobot Corp. (IRBT), Honda Motor Company (HMC) and Impax Laboratories (IPXL).

Helmerich & Payne (HP) was down $0.76, to close at $57.67, a loss of 1.30 percent.

Carnival Corp. (CCL) fell $0.76 on the day to close at $40.18, a loss of 1.86 percent.

IRobot Corp. (IRBT) dropped $0.75 to close at $33.47, a loss of 2.19 percent.

Honda Motor Company (HMC) declined $0.75 to close the session at $38.05, a loss of 1.93 percent.

Impax Laboratories (IPXL) plunged $0.74 to end the day at $27.40, a loss of 2.63 percent.

Price Targets On (HAIN) (IPXL) (KNXA) (LVS) (MA) Updated by Analysts

Analysts have updated their price targets on The Hain Celestial Group, Inc. (NASDAQ: HAIN), Impax Laboratories, Inc. (NASDAQ: IPXL), Kenexa Co. (NASDAQ: KNXA), Las Vegas Sands Corp. (NYSE: LVS) and MasterCard (NYSE: MA).

Citigroup (NYSE:C) raised their price target on The Hain Celestial Group, Inc. (HAIN) from $34.00 to $42.00. They have a “buy” rating on the company.

Goldman Sachs (NYSE:GS) raised their price target on Impax Laboratories, Inc. (IPXL) to $29.00. They have a “neutral” rating on the company. They also boosted their EPS estimates on Impax after stronger guidance.

Feltl & Co. raised their price target on Kenexa Co. (KNXA) from $33.00 to $35.00. They have a “strong buy” rating on the company.

Credit Suisse (NYSE:CS) cut their price target on Las Vegas Sands Corp. (LVS) from $56.00 to $55.00. They have an “outperform” rating on the company.

FBR Capital raised their price target on MasterCard (MA) from $290.00 to $330.00. They have an “outperform” rating on the company.

Impax (IPXL) Jumps on IPX066 Outlook

Shares of Impax Laboratories Inc. (NASDAQ:IPXL) rocketed up by almost 16 percent, after announcing its phase III clinical study of the safety and efficacy of IPX066 for the treatment of Parkinson’s disease showed “statistically significant, positive” results.

The share price is the highest the company, which makes generic drugs, has reached since going public in 1995.

Impax closed Tuesday at $25.52, gaining $3.45, or 15.63 percent.